Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
Cardio Diagnostics' mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care.
Spotlight on PrecisionCHD™ and Actionable Clinical Intelligence (ACI™)
PrecisionCHD™, Cardio Diagnostics' flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD™ is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD™ provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient.
Importantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD™ serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD™ empowers cardiologists to refine treatment plans based on a patient's unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes.
This year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI™) report for PrecisionCHD™, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI™ leverages PrecisionCHD™'s six key methylation markers, giving prescribing clinicians sharper visibility into their patients' modifiable drivers of disease, including inflammation-related risk - a critical advancement for personalized care.
'PrecisionCHD™ and our enhanced Actionable Clinical Intelligence™ deliver a level of insight that no other solution offers cardiologists today,' said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. 'By integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient's modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.'
Poster Presentation - Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology
At ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD™ test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes.
The poster, titled 'Synergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,' highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk.
By interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD™ can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes.
'These findings underscore the power of methylation-based biomarkers in cardiovascular medicine,' said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. 'Traditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.'
Visit Cardio Diagnostics at Booth #2033
Attendees are invited to visit Booth #2033 to learn more about the Company's PrecisionCHD™, Epi+Gen CHD™ and Actionable Clinical Intelligence™ solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company's executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Investor Relations
855-226-9991
[email protected] & Public Relations
Public Relations
855-226-9991
SOURCE: Cardio Diagnostics Holdings, Inc.
Copyright Business Wire 2025.
PUB: 03/26/2025 08:31 AM/DISC: 03/26/2025 08:32 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
29 minutes ago
- Time Business News
Vaginal Rejuvenation for Comfort and Wellness
Women's bodies go through many changes over the years. Among these natural shifts, changes in vaginal tissue can sometimes cause discomfort or affect personal confidence. Factors like aging, childbirth, and hormonal changes may lead to reduced firmness and elasticity of vaginal walls. While these changes are part of life, they can sometimes cause issues such as decreased sensation or mild discomfort during daily activities. Fortunately, advancements in medical technology provide safe and effective solutions to help restore vaginal wellness without surgery. Vaginal laxity happens when the tissue in the vaginal walls loses some of its tightness and strength. This is often due to a decline in collagen production. Collagen, a protein essential for skin elasticity, decreases naturally with age and other life events. Pregnancy and childbirth can stretch the vaginal muscles and tissues. Menopause and related hormonal changes can also contribute to reduced tissue quality and moisture levels. Laxity can affect overall comfort and may reduce sensation during intimate moments. It can also sometimes cause a feeling of looseness that impacts confidence and well-being. Additionally, mild urinary leakage and irritation can occur due to weakened pelvic support. These symptoms are common and can be managed effectively with proper care and treatment. Many women seek treatments that do not require surgery or extensive downtime. Non-invasive procedures, such as the Geneveve™ treatment, offer an excellent option. Geneveve™ uses gentle radiofrequency energy combined with a cooling system to stimulate the body's natural collagen production. This helps restore firmness and tone gradually without any incisions or discomfort. The Geneveve™ procedure is designed to be comfortable and safe. Its unique cooling technology protects the outer layers while treating deeper tissue to encourage collagen remodeling. Most patients experience improvements after a single session, with increased tissue tightness developing over a few weeks. The procedure supports vaginal health by improving tissue quality, which may also help reduce mild urinary issues. Ideal candidates are women experiencing mild to moderate laxity who want a non-surgical solution. Good overall health is important, and those with implanted electronic devices should consult their healthcare provider. A thorough medical evaluation ensures the treatment is suitable and sets realistic expectations for outcomes. Geneveve™ treatments are typically completed in under an hour. Patients lie comfortably while a device delivers controlled radiofrequency energy to the vaginal tissue. The cooling system helps keep the surface comfortable. Since there are no cuts or anesthesia, patients can usually return to normal activities immediately after the session. No downtime is needed after treatment. Patients are usually advised to wait about a week before resuming intimate activity to allow tissue healing. Results build gradually as collagen regenerates, leading to improved firmness, moisture, and overall comfort. Benefits often last many months, with some women choosing maintenance treatments. Beyond improved comfort and sensation, vaginal rejuvenation can: Help with mild urinary incontinence Reduce vaginal dryness and irritation Boost confidence in personal well-being Support healthier vaginal tissue If changes in vaginal health are causing discomfort or impacting quality of life, consulting a specialist is a wise step. A professional evaluation will help determine the best treatment approach. Non-surgical options like Geneveve™ offer a modern, safe way to regain comfort and wellness in a natural manner. Is the Geneveve™ treatment safe? Yes, it is FDA-cleared and designed to be safe for most women without implanted electronic devices. How long does the treatment take? Sessions usually last under an hour. Is there any pain during the procedure? Most patients find the treatment comfortable thanks to the cooling technology. How soon will I see results? Results typically appear gradually over several weeks as collagen increases. Are there side effects? Side effects are rare and mild, such as temporary swelling or warmth. Will this treatment help with mild urinary leakage? It may improve mild symptoms by strengthening vaginal and pelvic tissue. TIME BUSINESS NEWS
Business Wire
an hour ago
- Business Wire
Babcock & Wilcox Closes Sale of Its Diamond Power International Business
AKRON, Ohio--(BUSINESS WIRE)--Babcock & Wilcox Enterprises, Inc. (NYSE: BW) announced today the closing of the previously announced sale of its Diamond Power International business to Austria-based Andritz AG for $177 million, subject to customary adjustments and expenses. About Babcock & Wilcox Headquartered in Akron, Ohio, Babcock & Wilcox Enterprises, Inc. is a leader in energy and environmental products and services for power and industrial markets worldwide. Follow us on LinkedIn and learn more at
Business Wire
an hour ago
- Business Wire
Cotiviti's Quality Measurement and Reporting Solution Achieves 25th Consecutive Year of HEDIS ® Measure Certification
SALT LAKE CITY--(BUSINESS WIRE)--Quality Engine, the administrative measure logic and sample processing component of Cotiviti's Quality Intelligence solution, has earned HEDIS ® Certified Measures™ status from the National Committee for Quality Assurance (NCQA) for Measurement Year (MY) 2025. HEDIS Measure Certification validates that Cotiviti's measures have been put through the thorough testing required to effectively support health plans with the HEDIS MY 2025 season. This milestone marks an industry-leading 25 consecutive years of certification, demonstrating Cotiviti's ability to adapt and serve as a long-term partner to health plans as the HEDIS program continually evolves. This milestone marks an industry-leading 25 consecutive years of certification, demonstrating Cotiviti's ability to adapt and serve as a long-term partner to health plans as the HEDIS program continually evolves. Share 'The ongoing transition to fully digital quality measurement requires health plans to have a quality improvement solution that not only meets the highest standards for accuracy, but continually evolves to meet and exceed new requirements,' said Emad Rizk, M.D., chairman, president, and CEO of Cotiviti. 'This achievement reflects Cotiviti's unwavering commitment to supporting our health plan clients. It speaks to the deep expertise we've built through decades of working with billions of data points, navigating complex measurement requirements, and helping our clients meet the changing demands of quality reporting.' Cotiviti's Quality Intelligence processes more than 147 million member lives reported to NCQA and serves as a comprehensive measurement and reporting solution that streamlines compliance while supporting HEDIS, state-specific, and other quality measure submissions. Newly launched in 2025, Cotiviti's Engagement Hub integrates with Quality Intelligence to drive coordination and efficiency through a centralized member engagement and reporting platform, enabling plans to close care gaps to ultimately improve quality scores. Further integrations within Cotiviti's quality improvement ecosystem support year-round quality improvement and enable better member health. When integrated with Cotiviti's Star Intelligence, Quality Intelligence provides a centralized platform for managing both HEDIS and Star Ratings, helping clients ensure consistency across programs and maintain compatibility with historical data to support accurate trending and projections. Cotiviti's scalable medical record retrieval and abstraction services also connect directly with the solution to enable end-to-end support for health plans throughout the HEDIS season. 'Payers need a trusted partner in quality improvement with a longstanding track record of success to help them navigate the digital quality transition and deliver high-performing, reliable solutions that have been continuously refined and supported over decades,' said Chad Kinkead, executive vice president of risk adjustment, quality, and engagement for Cotiviti. 'Cotiviti's Quality Intelligence supports all members and lines of business with end-to-end capabilities for accurate processing, reporting, audits, and submissions, backed by a team of experts who are committed to supporting health plans during and after the transition to digital reporting. Our clients can anticipate further innovation as we integrate Cotiviti's industry-leading quality improvement, DxCG risk assessment, engagement, and risk adjustment solutions with Edifecs ' leading NLP-enabled coding platform, interoperability capabilities, and AI-enabled value based-payment solutions." About Cotiviti Cotiviti enables healthcare organizations to deliver better care at lower cost through advanced technology and data analytics that improve the quality and sustainability of healthcare in the United States. Cotiviti's solutions increase transparency and collaboration between payers and providers while empowering them to reduce medical and administrative costs, enable better health, improve claims payment efficiency, streamline operations, drive interoperability, and advance value-based care. Its customers serve the majority of U.S. healthcare consumers, providing coverage and care for over 300 million members and patients. Additionally, Cotiviti offers data management and recovery audit services to the retail sector to improve business outcomes. For more information, visit About NCQA NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA accredits and certifies a wide range of healthcare organizations. It also recognizes clinicians and practices in key areas of performance. NCQA's website contains information to help consumers, employers and others make more informed healthcare choices.
